Johnson & Johnson announces two-year Icotyde data in difficult-to-treat plaque psoriasis

Johnson & Johnson reported Icotyde-treated patients had 70% clear or almost clear skin at week 112; 60% with scalp psoriasis and 89% with genital psoriasis achieved complete clearance. Safety findings through week 112 were consistent with Icotyde’s profile, with no new safety signals.